MeiraGTx

MeiraGTx is a clinical-stage, vertically integrated genetic medicines company founded in 2015 by Alexandria Forbes and Richard Giroux. The company, with primary locations in New York and London, focuses on developing treatments for a range of inherited and acquired disorders. President and CEO Alexandria Forbes has a background that spans a successful academic career in molecular genetics at Oxford and Cambridge to over a decade as a healthcare investor, providing a foundation in both the scientific and financial aspects of biotechnology. Co-founder Richard Giroux, who serves as COO and CFO, brings extensive experience from the hedge fund and investment banking sectors, having worked at firms like Sarissa Capital Management, Meadowvale Partners, and Goldman Sachs.

The company's core technology includes a proprietary riboswitch gene regulation platform, which allows for the precise, dose-responsive control of gene expression through orally administered small molecules. This platform is designed to switch gene expression on and off, offering a high degree of control over therapeutic proteins. MeiraGTx's business model is centered on advancing its pipeline of gene therapy candidates through clinical trials, with a focus on diseases of the eye, central nervous system (CNS), and salivary gland. The company's pipeline includes late-stage clinical programs for conditions such as Parkinson's disease, radiation-induced xerostomia, and inherited retinal diseases like Leber Congenital Amaurosis (LCA4) and X-Linked Retinitis Pigmentosa (XLRP).

MeiraGTx generates revenue through strategic collaborations and service agreements. It has engaged in significant partnerships, including a collaboration with Janssen (a Johnson & Johnson company) for its XLRP program and a strategic investment from Sanofi to provide a first look at data from its riboswitch platform. More recently, a collaboration with Hologen AI was established to advance the AAV-GAD program for Parkinson's disease. The company supports its extensive pipeline with end-to-end in-house manufacturing capabilities, including multiple GMP-licensed viral vector production facilities in the US and Ireland, which are intended to provide control over its supply chain and reduce costs.

Keywords: gene therapy, riboswitch gene regulation, clinical-stage biotechnology, AAV vectors, genetic medicines, inherited retinal diseases, Parkinson's disease, xerostomia, oral small molecules, viral vector manufacturing, metabolic diseases, cell therapy, CNS disorders, ophthalmology, drug development